Liquid biopsy predicts response to breast cancer immunotherapy
Immunotherapy has become a standard of care in treating high-risk, early-stage breast cancers, yet it has had limited success in shrinking tumors. New biomarkers that can improve outcomes for patients are urgently needed. ...
May 3, 2026
0
20









